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Summary
The concept of managing obesity through the stimulation of thermogenesis is
currently a focus of considerable attention by the pharmaceutical, nutraceutical
and functional food industries. This paper ﬁrst reviews the landmark discoveries
that have fuelled the search for thermogenic anti-obesity products that range
from single-target drugs to multi-target functional foods. It subsequently analy-
ses the thermogenic and fat-oxidizing potentials of a wide array of bioactive
food ingredients which are categorized under methylxanthines, polyphenols,
capsaicinoids/capsinoids, minerals, proteins/amino acids, carbohydrates/sugars
and fats/fatty acids. The main outcome of this analysis is that the compounds or
combination of compounds with thermogenic and fat-oxidizing potentials are
those that possess both sympathomimetic stimulatory activity and acetyl-coA
carboxylase inhibitory property, and are capable of targeting both skeletal
muscle and brown adipose tissue. The thermogenic potentials of products so far
tested in humans range from marginal to modest, i.e. 2–5% above daily energy
expenditure. With an increasing number of bioactive food ingredients awaiting
screening in humans, there is hope that this thermogenic potential could be
safely increased to 10–15% above daily energy expenditure – which would have
clinically signiﬁcant impact on weight management, particularly in the preven-
tion of obesity and in improving the long-term prognosis of post-slimming
weight maintenance.
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Introduction
In this era when information technology is revolutionizing
health awareness among the general public, more and more
people are increasingly conscious of the health hazards of
excess body fat. This change in perception of excess adi-
posity from a ‘cosmetic’ to a ‘health’ issue is encouraging as
it is now acknowledged by the medical establishment that
even a modest degree of obesity, particularly if the excess
fat is located in the abdomen (1), increases the risks for
chronic diseases traditionally associated with more severe
obesity, namely type 2 diabetes, cardiovascular diseases
and some forms of cancer. However, the cornerstone
methods for managing body weight – by dietary restriction
and/or by exercise – have proven to be largely ineffective as
few people can stick to the hardships of dietary regimens
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for a long time, and compliance to regular exercise is
equally poor. The result is generally a transient phase of
weight loss (or weight stability) followed by a return on the
trajectory towards obesity. These failures to prevent and
treat obesity have led to a re-examination of classical views
about the causes of this disorder, and indeed a reconsidera-
tion of the general concepts of homeostatic mechanisms
that regulate body weight and body composition. Although
the increasing prevalence of obesity is associated with an
environment that encourages over-eating and discourages
physical activity, it is now recognized that genetic suscep-
tibilities for a ‘slow metabolism’ – characterized by a low
resting energy expenditure (EE), a low capacity to burn
surplus food via diet-induced thermogenesis and/or a low
capacity for fat oxidation – also play an important role in
determining the extent to which an individual resists or is
prone to obesity (2–5). Furthermore, it has long been
known that in response to reduced food intake and weight
loss (induced by dieting or with the help of anorectic
agents), there is an accompanying reduction in EE which is
in part due to loss of lean body mass, and in part due to an
enhanced metabolic efﬁciency (6–8). Such reductions in
thermogenesis may also persist well beyond the phase of
weight loss (9,10), and have been demonstrated in both the
resting and non-resting compartments of daily EE (10).
These energy-sparing mechanisms not only are counterpro-
ductive to the efﬁcacy of the dietary regime in achieving the
target weight, but also contribute importantly to weight
regain and obesity relapse. Approaches that could dampen
these compensatory mechanisms and counteract metabolic
predispositions to fatness during weight gain or weight
regain are therefore appealing adjuvants to assist the man-
agement of obesity. It is towards these conditions of ‘slow
metabolism’ – characterized as diminished thermogenesis
and fat oxidation – that considerable research vis-a-vis
obesity therapy is directed: that is to say, there is an active
search for means of increasing thermogenesis and fat oxi-
dation in weight management.
The search for thermogenic compounds: from
a historical perspective
From thyroid extracts to sympathomimetics
The idea of stimulating thermogenesis to manage or to
assist in the management of obesity has a long history.
Thyroid extracts were utilized in obesity therapy at the end
of the 19th century, and a few decades later, thousands of
obese patients were treated with thyroid hormones and
uncoupling agents like dinitrophenol (11). Although they
induced marked reductions in body weight, their use in
obesity therapy fell into disrepute because of unacceptable
side effects, including cardiac stimulation and increased
protein catabolism. Numerous other compounds, which
can be categorized under hormones (e.g. glucagon, growth
hormone), synthetics (e.g. dinitrophenol derivatives,
vasodilators such as nicotinic acid, salicylates) or foods
(e.g. certain amino acids like glycine, citrus extract, liebig
extract), were subsequently tested for thermogenic proper-
ties, but their effects on metabolic rate were found to be
either insigniﬁcant or of too short duration (12). Other
compounds like caffeine, theophylline and ephedrine,
whose use as bronchodilators in the treatment of asthma
peaked in the 1950s, were also long known to have sym-
pathomimetic properties with signiﬁcant stimulatory
effects on resting EE (13,14). Interests in these drugs
capable of mimicking or enhancing the calorigenic effects
of catecholamines for weight control only surged in the
early 1980s when the pivotal role of the sympatho-adrenal
system in the defence of le milieu intérieur was extended to
the body’s fat stores. This followed several lines of evidence
suggesting an important role for the sympathetic nervous
system (SNS) (via its heat-producing neurotransmitter
noradrenaline, NA) in dietary regulation of thermogenesis,
and that low SNS activity may contribute to the diminished
EE that underlies susceptibility to fatness (15,16). Speciﬁ-
cally in the context of dietary management of obesity, the
suppression of SNS activity by caloric restriction appears to
play an important role in the accompanying adaptive
reduction in thermogenesis (15). Hence, compounds that
mimic the activity of the SNS and increase thermogenesis
therefore offer therapeutic potential, and provide a rational
approach in obesity treatment. Additional motivations in
the search for sympathomimetic compounds gained
momentum in the late 1980s following evidence in support
of the notion that fat balance, unlike carbohydrate and
protein balances, is not precisely regulated, and that the
failure to adjust fat oxidation in response to excess fat
intake will result in decreased satiety and increased energy
intake (17). Consequently, sympathomimetics have been
viewed as agents that – via their stimulatory effects on both
thermogenesis and fatty acid oxidation – are capable of
exerting their anti-obesity effects by increasing EE and fat
oxidation while decreasing appetite.
From classical sympathomimetics to atypical
adrenoceptor agonists
By the early 1990s, virtually all sympathomimetic drugs
then in clinical use for a variety of other treatments had
been screened for thermogenic anti-obesity properties (18),
and the thermogenic properties of clinically relevant doses
of caffeine or ephedrine were established not only in lean
but also in obese and post-obese humans (19–23). Further-
more, the demonstrations that sympathomimetic stimula-
tion of thermogenesis induced by ephedrine could be
potentiated by low doses of methylxanthines (theophylline
and/or caffeine) (24,25) or by salicylates like aspirin
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(26,27) – via mode of interactions (28) depicted in Fig. 1 –
led to the conduct of several controlled clinical trials which
showed that various combinations of these drugs had
modest anti-obesity efﬁcacy and were well tolerated with
side effects considered mild and mostly transient (29–32).
There was, however, little or no enthusiasm by the phar-
maceutical industry to promote the sale of such sympatho-
mimetic drug cocktails as thermogenic anti-obesity drugs
for reasons that included (i) issues of patentability for
putting these ‘old’ drugs (often available over-the-counter)
to a new purpose; (ii) risks for hypertension, tachycardia
and tremor associated with drugs that could be acting on
classical (a1, b1 and b2) adrenoceptors among a broad
spectrum of the population, many of whom may have
unrecognized risk factors and (iii) the belief that more
selective, safer and more efﬁcacious novel sympathomimet-
ics in development by some pharmaceutical companies
would soon become available. It was indeed one of these
novel adrenergic agonists that led to the demonstration of
atypical adrenoceptors that were eventually cloned and
referred to as b3-adrenoceptors (33). The pharmaceutical
approach has since concentrated on the development
of drugs that would target speciﬁcally atypical b3-
adrenoceptor, believed to be the pivotal receptor via which
sympathetically released NA activates thermogenesis and
fat oxidation in peripheral tissues (Fig. 2), including the
activation of uncoupling protein (UCP1) that mediates
thermogenesis in brown adipose tissue (BAT). In rodents
and dogs, several b3-adrenoceptor agonists were shown to
have potent thermogenic anti-obesity effects – without pro-
ducing the cardiovascular side effects associated with clas-
sical adrenoceptor stimulation (34). However, despite the
demonstration that b3-adrenoceptors are also present in
human adipose tissue and skeletal muscle, the translational
research from rodents to humans proved disappointing.
Whereas the ﬁrst-generation compounds had poor selectiv-
Figure 1 Sympathetically mediated
noradrenaline (NA) release and actions (via
b-adrenoceptors) are under negative-feedback
modulation by (i) adenosine, certain
prostaglandins and catechol-O-methyl
transferase (COMT) in synaptic neuroeffector
junction and (ii) at cellular level, by
phosphodiesterases which break down
NA-induced cyclic AMP. Thus, when NA
release is enhanced by food ingestion or
pharmacologically (e.g. by ephedrine), the
inhibitory effects of adenosine, COMT and
phosphodiesterases on further NA release and
actions could be opposed by xanthines (e.g.
caffeine), salicylates (e.g. aspirin) or ﬂavonoid
polyphenols (e.g. green tea catechins). Thus,
the stimulatory effect of NA on thermogenesis
and fat oxidation could be increased and/or
prolonged. Adapted from Dulloo (28).
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Figure 2 Concepts in targeting the peripheral adrenergic system in
anti-obesity therapy (adapted from Dulloo (28)). See text for details.
Adr, adrenaline; BAT, brown adipose tissue; CNS, central nervous
system; NA, noradrenaline.
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ity as agonists of the human cloned b3-adrenoceptor,
the second-generation compounds, which showed greater
selectivity for human b3-adrenoceptors, had poor oral
bioavailability or were rapidly excreted. Moreover,
b3-adrenoceptor agonists have less effect on EE in humans
than in rodents, and although some compounds when
administered over a few weeks led to weight loss, this was
too modest to be considered sufﬁciently exciting for longer
trials (34). Overall, despite the attempts of many pharma-
ceutical companies to develop b3-adrenoceptor agonists for
the treatment of obesity, there is no report of a compound
that has progressed beyond phase II clinical trials (34).
From b3-adrenoceptor agonists to acetyl-CoA
carboxylase 2 inhibitors
A turning point in the search for molecular targets to
enhance fat oxidation occurred in the early 2000s with
the implication of the AMP-activated protein kinase
(AMPK) signalling pathway in the stimulation of fatty
acid oxidation by the leptin–SNS axis (35). Activation of
AMPK is thought to convey many of the beneﬁcial effects
of exercise by inhibiting the activity of the enzyme acetyl-
CoA carboxylase 2 (ACC2), thereby facilitating the entry
of fatty acyl-CoA into the mitochondria leading to
increased fat oxidation. The demonstrations that mice
with deletion of the ACC2 gene are resistant to obesity
(36) and show increased fatty acid oxidation coupled
with elevated whole-body EE (37) provided considerable
support to the concept of ‘push’ routes to increased fat
oxidation (38) in that increased ﬂux of fatty acids into
mitochondria might be sufﬁcient to trigger increased
whole-body EE and leanness. Although the mechanisms
by which an enhanced fat oxidation would drive energy
dissipation are not understood, AMPK and ACC2 have
become major anti-obesity and anti-diabetes drug targets
(39). However, a recent re-examination of this relation-
ship between increased fatty acid oxidation and reduced
adiposity using both pharmacological and genetic
approaches (mutation of the ACC2 gene in mice) does
not support the hypothesis that increased fatty acid oxi-
dation per se leads to diminished body fat (40). Although
both of these strategies increased whole-body fatty acid
oxidation, they failed to increase EE and to reduce adi-
posity, the previous reports of the opposite being attrib-
uted to technical issues and artefacts in mouse genetic
manipulation (40). The more recent ﬁndings in mice (40)
are consistent with other studies in rats showing that a
non-selective ACC1/2 inhibitor decreased respiratory quo-
tient over a 3-h period without altering EE (41) and that
reduced ACC1/2 expression in rat liver and adipose tissue
using antisense oligonucleotides was without effect on
body weight (42). Taken together, these data indicating
that fat oxidation and thermogenesis are not necessarily
coupled cast serious doubts about the belief that fat oxi-
dation per se drives leanness. Rather, the increased fat
oxidation may be offset by alterations in the handling of
other macronutrients, and hence consistent with the
glucose–fatty acid cycle proposed by Randle 50 years ago
(43). In this context, the question arises as to whether
drug targeting of fat oxidation at the expense of carbo-
hydrate oxidation is desirable as this could lead to
impaired glucose uptake by metabolic feedback. This
issue of whether it is good or bad to increase fat oxida-
tion (in the absence of an increase in EE) pertaining to
substrate competition and insulin sensitivity is discussed
in greater depth by Kiens et al. (44) in an accompanying
article about potential targets in the regulation of fat
metabolism.
From pharmacotherapy to phytotherapy
The difﬁculties of the pharmaceutical industry in produc-
ing drugs with good efﬁcacy, selectivity and pharmacoki-
netic properties suitable for stimulation of the small
number of b3-adrenoceptors present in humans, uncertain-
ties about the future of research and development for
ACC2 inhibitors, together with the lack of interest in mar-
keting ephedrine, caffeine and/or aspirin combinations for
anti-obesity therapy, have created and sustained a vacuum
in the market for pharma-grade thermogenic products.
This vacuum has long been ﬁlled by the commercialization
of a plethrora of botanical or herbal products, whose phar-
macologically active ingredients would act at one or more
control points along the line of SNS control of thermogen-
esis and fat oxidation (Fig. 1). It is estimated that some 12
million people in the USA utilized these herbal supple-
ments in 1999 alone (45), often as mixtures of Ma Huang
(a source of ephedra alkaloids), Guarana or kola nuts
(sources of caffeine), bark of willow (source of salicylates),
and Coleus Forskohlii whose active ingredient – forskolin
– enhances cAMP formation through stimulation of ade-
nylate cyclase. Not surprisingly, their sales under the cat-
egory of dietary supplements were promoted with the
ﬁndings of safety and efﬁcacy derived from controlled
studies with pharmaceutical grades of these compounds
(29–32), and subsequently by a few short-term small-size
clinical trials reporting weight loss efﬁcacy and relative
safety of herbal preparations of ephedra and guarana or
kola nuts (46,47). However, because of the publicity of
adverse reactions to ephedra-containing products and the
high potential for abuse when such botanical products are
available to the general public, many of whom may have
unrecognized risk factors, the sales of ephedra has been
banned in the USA and other countries (48). As a result,
many companies have since altered their botanical prepa-
rations by substituting ephedra with Citrus aurantium
(bitter orange), whose major bioactive ingredients are

ht
tp
://
do
c.
re
ro
.c
h
synephrine alkaloids, which act on both a- and
b-adrenoceptors and which have been shown to increase
resting EE acutely in humans (49). At present, Citrus
aurantium is considered by some to be the best ther-
mogenic substitute for ephedra (50), but the few small-size
short-duration studies that have reported greater weight
losses with Citrus aurantium products cannot be consid-
ered as conclusive regarding the safety and efﬁcacy, and
furthermore they do not separate the effects of Citrus
aurantium from those of other ingredients in these prod-
ucts (51). Among other herbal products for weight control
with claims (52) for their fat oxidation properties is Gar-
cinia cambogia, a natural fruit acid extracted from the rind
of the brindall berry which contains (-)-hydroxycitrate – a
compound which Sullivan et al. (53) showed in the early
1970s to potently inhibit the extramitochondrial enzyme
citrate lyase, a key enzyme involved in de novo lipogenesis.
Thus, by inhibiting the lipogenic machinery, hydroxyci-
trate has the potential to shift fat metabolism from
synthesis/storage towards oxidation. However, the ﬁndings
from a controlled study that 3 d of hydroxycitrate (3 g d-1)
supplementation to a typical Western diet failed to alter the
short-term rate of fat oxidation (54) raise doubts about the
purported mode of action of hydroxycitrate per se. Fur-
thermore, studies that have provided evidence in support
of the efﬁcacy of hydroxycitrate in weight loss are those
in which hydroxycitrate was administered together with
other ingredients, so that the anti-obesity efﬁcacy of
hydroxycitrate per se cannot be evaluated. A randomized
double-blind placebo-controlled trial lasting for 3 months
found no difference in body weight nor body fat losses in
subjects receiving the active herbal compound containing
hydroxycitrate (1,500 mg d-1) compared to placebo (55).
From phytotherapy to functional food ingredients
Although the market for weight-loss products that con-
tain a multitude of sympathomimetics and claimed fat-
oxidizing ingredients continues to ﬂourish, the past decade
has also seen growing interests by mainstream pharmaceu-
tical and food industries towards the development of ther-
mogenic and ‘fat-burning’ nutraceuticals or functional
foods. This has invigorated both basic and applied research
into the area of bioactive food ingredients for weight man-
agement, leading to investigations into an increasing array
of dietary micro-components, but also macro-components,
that cut across both plant and animal products for poten-
tial stimulatory effects on thermogenesis and fat oxidation.
An overview of this rapidly advancing research ﬁeld is
presented below, with the focus on food ingredients derived
from fruits, vegetables, herbs, spices, meat and dairy prod-
ucts, and categorized under methylxanthines, polyphenols,
capsaicinoids/capsinoids, minerals, proteins/amino acids,
carbohydrates/sugars and fats/fatty acids.
Bioactive food ingredients: thermogenic and
fat-oxidizing potentials
Methylxanthines
The ability of caffeine – the most abundant dietary meth-
ylxanthine – to stimulate metabolic rate was demon-
strated in humans almost a century ago (13). Studies
conducted several decades later, in the 1980s, established
that caffeine was also effective in stimulating resting EE in
both the post-absorptive and postprandial states in lean,
obese and post-obese subjects (19–21), often associated
with increases in circulating free fatty acid and fat oxida-
tion (19,20). Using indirect calorimetry coupled with 13C-
labelled palmitate measurements to trace lipid oxidation
and free fatty acid turnover, Acheson et al. (56) have
more recently shown that although caffeine ingestion
(10 mg kg-1) in young men increased resting EE by 13%
and caused a doubling in fatty acid turnover, only 24%
were oxidized, indicating that most mobilized fatty acids
are recycled through re-esteriﬁcation. They proposed that
as exercise causes an increase in the turnover of fatty
acids, of which most (70–80%) are oxidized (57), the
combined stimulation of lipolysis by caffeine administra-
tion and stimulation of EE by exercise may prove more
effective in enhancing fat oxidation than giving caffeine
alone. An analysis of literature data on the effect of
single-dose administration of caffeine on resting EE after
an overnight fast suggests a dose–effect relationship with
the threshold for a detectable stimulatory effect (+5%)
occurring between 50 and 100 mg – which corresponds to
the amount of caffeine in a cup of coffee or tea. Repeated
administration of such low doses of caffeine (100 mg) at
regular 2-h intervals between 8:00 h and 18:00 h (i.e.
total of 600 mg d-1), during time spent in a whole-body
respiratory chamber, was found to increase 24-h EE by
5% in both lean and post-obese individuals (21). Simi-
larly, repeated intake of caffeinated coffee, containing
higher doses of caffeine (250 mg per cup, ﬁve cups per
day, i.e. 1,250 mg d-1), was also shown to increase 24-h
EE by 8% and 5% in lean and obese subjects respectively
(58), without apparent side effects, no difference in heart
rate nor alterations in protein oxidation or non-protein
respiratory quotient, suggesting an increase in both fat
and carbohydrate oxidation. There was, however, a ten-
dency for respiratory quotient to be lower during sleep,
and a signiﬁcant decrease in respiratory quotient relative
to placebo was observed the following morning, sugges-
tive of a selective increase in post-absorptive fat oxidation
(58). Despite these quantitatively important thermogenic
effects of caffeine when assessed over 24 h under weight
maintenance conditions (21,58), obese individuals ingest-
ing 200 mg three times a day (600 mg d-1) in conjunction
with a hypocaloric diet lost no more weight than those on
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placebo (29). Overall, caffeine certainly possesses substan-
tial thermogenic properties (fuelled partially or almost
completely by lipids), which might assist in the prevention
of weight gain and weight regain, but these effects would
seem to be absent during the dynamic phase of weight
loss in response to caloric restriction, possibly because of
the accompanying reduction in SNS activity, and hence
less negative modulators of NA release and action (e.g.
adenosine, phosphodiesterase activity) to inhibit (Fig. 1).
This contention is supported by the fact that low doses
of methylxanthines (theophylline and/or caffeine) were
found to be effective in potentiating the thermogenic
effects of the NA-release enhancer ephedrine (24,25), and
that a combination of ephedrine and caffeine resulted in
greater fat losses than either ephedrine or caffeine alone
in women on a hypocaloric diet (29).
Polyphenolic compounds
Although the role of plant polyphenols in health and dis-
eases has been an active area of research for many decades,
interest in the potential role of these phytochemicals in
energy metabolism and obesity research is only a decade
old. This followed the demonstration (59) that ingestion of
capsules of a green tea extract – providing 125 mg catechin
polyphenols and 50 mg caffeine with each of three meals
over the day, resulted in a 4% increase in 24-h EE, a shift
from carbohydrate to fat oxidation and increased urinary
NA excretion – metabolic effects that were not found to be
mimicked by ingestion of the same amount of caffeine as
found in the green tea extract (59). Given evidence that
polyphenols of the class of ﬂavonoids, which includes cat-
echins, are capable of inhibiting catechol-o-methlyl trans-
ferase (COMT) (60–62), an enzyme that degrades NA
(Fig. 1), the proposal was put forward that by virtue of its
content in both catechin polyphenols (which may hence
reduce the degradation of NA within the synaptic cleft) and
caffeine (which inhibits phosphodiesterase within the cyto-
plasm), green tea has thus the potential to interact syner-
gistically with the SNS leading to the potentiation and
prolongation of NA-induced thermogenesis and fat oxida-
tion (59). Such mechanistic proof-of-concept was subse-
quently supported by ex vivo microcalorimetry studies (63)
in rat BAT, which demonstrated synergistic thermogenic
interactions between sympathetic neural release of NA,
caffeine and epigallocatechin gallate (EGCG), the most
abundant of green tea catechins. Further evidence that caf-
feine and EGCG interact to enhance 24-h EE in humans
may also be obtained from an analysis of data (reported
here in Fig. 3) derived from several studies that compared,
by regression analysis, the increase in 24-h EE in response
to the intake of different doses of caffeine (21,58,59,64)
versus that in response to intake of green or oolong
tea products containing both caffeine and catechins, the
1  Dulloo et al. (21)
2  Bracco et al. (58)
3  Dulloo et al. (59)
4  Rumpler et al. (64)
5  Bérubé-Parent et al. (65)
6  Rudelle et al. (66)
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Figure 3 Regression analysis of data on mean changes in 24-h energy expenditure (EE), assessed in respiratory chambers, in non-obese humans in
response to either caffeine (21,58,59,64) presented as ﬁlled circles or to green or oolong tea products containing both caffeine and catechins
(59,64–66) presented as open circles and in which the epigallocatechin gallate (EGCG) intakes are similar across these studies – within the narrow
range of 244–282 mg d-1. The black and grey ﬁlled circles for study 1 (21) represent data for never-obese and post-obese subjects, respectively. The
open triangles (in study 5) represent additional data (65) in response to green tea products containing much higher amounts of EGCG, namely 600,
900 and 1,200 mg; they are not part of the regression analysis here. Statistical comparisons of the two regression lines for equality of variance,
slopes and elevations indicate signiﬁcant differences (P < 0.05) only in their elevations. The data were analysed by the computer software STATISTIK
8 (Analytical Software, St Paul, MN, USA). Note also that within the study 5 (65), there is a graded increase in mean 24-h EE in response to 600-mg
caffeine and varying intakes of catechins as EGCG – namely 270, 600, 900 and 1,200 mg d-1 designated as 5a, 5b, 5c and 5d, respectively.
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intake of EGCG being similar (244–282 mg d-1) across
these studies (59,64–66). This regression analysis suggests
that for the caffeine intake across the range of 150–
600 mg d-1, the increase in 24-h EE is shown to be greater
with products containing both caffeine and EGCG than
caffeine alone. Furthermore, the data of Bérubé-Parent
et al. (65) suggest a tendency towards a dose–response
increase in 24-h EE with increasing EGCG intake in the
range of 270–1,200 mg in combination with 600 mg of
caffeine. A number of studies have also addressed the ques-
tion of whether green tea catechins, in their own rights (i.e.
in the absence of caffeine), can enhance EE and fat oxida-
tion. In this context, a caffeine-free green tea extract has
been reported to improve fat oxidation during moderate-
intensity cycling exercise in healthy young men (67), while
the ingestion of a commercially available EGCG supple-
ment was found to be effective in enhancing postprandial
fat oxidation at rest in overweight/obese men (68), but not
in lean men (69). A common denominator in the latter
studies is that none of them found an increase in resting EE
in response to ingestion of the commercially available
EGCG (68,69). Taken together, these results underscore the
possibility that in humans, in line with what was demon-
strated by microcalorimetry studies in rat BAT (63), the
thermogenic effects of green tea reside in the synergistic
interactions between catechins, caffeine and sympatheti-
cally released NA. These interactions along the NA–cAMP
pathway may thus require a modest enhancement in sym-
pathetic tone as would occur after meals and/or during the
type of low-level spontaneous activity that humans often
exhibit even during conﬁnement in respiratory chambers
(70). It should also be noted that studies lasting for 13.5 h
to 24 h in respiratory chambers show a greater tendency
(albeit not always statistically signiﬁcant) for a reduction in
respiratory quotient (i.e. selective increase in fat oxidation)
in response to ingestion of green tea products containing
both caffeine and catechins than with caffeine alone
(59,64,65,71) – a contention which is reinforced by the
results of a recent meta-analysis by Hursel et al. (72). These
thermogenic effects of green tea fuelled at least in part by
an increase in fat oxidation may thus contribute impor-
tantly to the reported efﬁcacy of green tea products in
inducing an extra 1–2 kg weight loss and/or abdominal fat
losses observed in controlled clinical trials lasting
from a few weeks to a few months (73,74), and to a better
post-slimming weight maintenance through increased ther-
mogenesis and fat oxidation (75). A mechanistic model that
integrates animal and human data to explain the anti-
obesity properties of green tea has recently been proposed
by Thavanesan (76).
Other polyphenols
During the past few years, a wide variety of polyphenolic
products and compounds belonging to several classes and
subclasses of polyphenols (in particular ﬂavonoids) have
also been shown to possess properties that could poten-
tially lead to enhance thermogenesis and fat oxidation,
namely:
1. A polyphenol-rich insoluble dietary ﬁbre preparation
from carob pulp (rich in gallic acid, gallotannins and
ﬂavonol glycosides) has been shown to increase post-
prandial EE and reduced respiratory quotient in humans
(77).
2. Resveratrol and quercetin, two quantitatively impor-
tant grape polyphenols, may possess such thermogenic
properties, as judged by studies showing that resveratrol
supplementation to mice fed on a high-fat diet resulted in
more hepatic mitochondria and elevated whole-body EE
(78), while quercetin supplementation to untrained humans
led to increases in skeletal muscle mitochondrial density
(79) as well as improved ﬁtness and endurance capacity
without prior training (80). There is no report yet about
whether these or other grape polyphenols impact upon
metabolic rate and substrate oxidation in humans, but this
would be an interesting line research in view of the recently
reported effects of polyphenol-rich grape extracts in pre-
venting obesity in hamsters (81), and weight gain in over-
weight men and women (82).
3. Oleuropein, a phenolic compound in extra virgin
olive oil, has been shown to enhance catecholamine secre-
tion and to increase UCP1 in BAT of rats (83), while lemon
polyphenols (hesperidin) suppress diet-induced obesity
associated with the up-regulation of gene markers of lipid
oxidation in mouse white adipose tissue (84).
4. Other polyphenols like circumin (rich in the spice
turmeric) or chlorogenic acid (rich in coffee beans) when
supplemented to mice on a high-fat diet resulted in lower
body weight and fat gain than controls, apparently without
a decrease in food intake, thereby raising the possibility
that the anti-obesity effects of these polyphenols reside
primarily in increasing faecal fat losses and/or via the
stimulation of EE (85,86).
5. Similarly, dietary supplementation with soy isoﬂa-
vones has been shown to decrease fat accumulation in
several animal models of obesity (87), and mice exposed to
dietary phytoestrogens maintain a lean phenotype associ-
ated with increased EE coupled with a marked shift
towards the use of lipids (88).
6. Finally, the small polyphenolic ﬂavonol molecule
kaempferol (found in broccoli, spinach, berries) increases
cellular EE and thyroid hormone activation through the
stimulation of deiodinase type 2 activity in human skeletal
muscle myoblast (89).
Thus, it is highly likely that in the coming years, polyphe-
nolic compounds will be a focus of research for ther-
mogenic anti-obesity effects in humans – a contention
reinforced by the results of a recent longitudinal analysis

ht
tp
://
do
c.
re
ro
.c
h
from the Netherland cohort study indicating that higher
dietary ﬂavonoid intakes in women are associated with
lower weight gain over a 14-year period (90).
Capsaicinoids and capsinoids
Interests in pungent spices as potentially containing
thermogenic ingredients were probably triggered by their
apparent ability to ‘subjectively’ warm the body. More
objective evidence for spice-induced thermogenesis was
ﬁrst provided by Henry and Emery (91), who showed
that chilli and mustard sauces augmented the thermogenic
response to a meal. This was followed nearly a decade
later by demonstrations of Yoshioka et al. (92) that red
pepper also enhanced thermogenesis and fat oxidation
in Japanese women. It is now established from animal
studies that the principle ingredients that confer pungency
to these spices (and to others such as Tabasco sauce and
ginger), namely the capsaicinoids (capsaicin and dihydro-
capsaicin) and capsaicinoid homologues (the gingerols,
shogaols and zingerone), contribute to their thermogenic,
lipolytic and fat-oxidizing properties (93). These meta-
bolic effects of pungent principles of spices are perhaps
not unexpected in view of evidence in animals suggesting
that their main modes of action can also be linked to
interference with the sympathoadrenal system, either cen-
trally to induce adrenal medullary secretion or peripher-
ally by interference with SNS control in tissues such as
muscle and adipose tissue (93). In humans, power spectral
analysis of heart rate has suggested that the anorexigenic
and thermogenic effects of red pepper in combination
with caffeine could be associated with an increase in sym-
pathetic : parasympathetic nervous system activity ratio
(94). It should be pointed out, however, that the red
pepper doses provided in the above-mentioned studies (up
to 10 g per meal) are high, and largely exceed the amount
preferred by the general population in many countries,
such as in the USA and Europe, where the intake is ~1 g
per meal. Given their strong pungency, not all people may
feel comfortable consuming several folds their habitual
intake. Interestingly, oral or capsular ingestion of hedoni-
cally acceptable red pepper doses, in single dose, has also
been shown to enhance thermogenesis (and to produce
moderate orexigenic sensations) in young adults sub-
grouped as spicy food users and non-users, with oral
exposure being shown to be necessary to achieve red pep-
per’s maximum effects on energy balance (95). Other
capsaicin-like compounds such as capsinoids (i.e. capsiate,
dihydrocapsiate and nordihydrocapsiate) are much less
pungent, but they can also increase the activity of the
SNS, thermogenesis and fat oxidation. In human subjects,
ingestion of capsinoids-rich peppers (CH-19 sweet; Cap-
sicum annuum) was found to increase body temperature
and resting EE (96), while ingestion of 10 mg of capsi-
noids was shown to increase plasma NA and EE at rest,
and resulted in a shift in substrate utilization towards
lipids (97). Furthermore, a signiﬁcant increase in resting
EE in response to 3–9 mg d-1 of dihydrocapsiate was
demonstrated in healthy subjects after daily intake of
capsinoid for 28 d (98). Thus, given the lack of pungency,
the use of capsinoids may represent a more viable
longer-term adjunct therapy for the management of
overweight and obesity as it has been shown to enhance
fat oxidation and reduce abdominal fat in overweight
individuals (99).
Minerals
A role for dietary calcium in the regulation of body weight
and body composition has been advocated by Zemel (100)
on the basis that dietary calcium, via its effects on plasma
1,25-dihydroxyvitamin D3 (calcitriol), regulates adipocyte
intracellular concentrations of calcium, which in turn regu-
lates lipid metabolism in the adipocytes. According to this
hypothesis, centred on the notion that a low dietary
calcium intake inhibits lipolysis, stimulates de novo lipo-
genesis and inhibits fat oxidation, a low dietary calcium
intake would lead to weight gain, whereas a high dietary
calcium intake would result in weight loss. This concept
was initially supported by studies in mice and human
showing that dietary calcium drives the partitioning of
energy towards lean body mass rather than adipose tissue,
particularly when the diet has a high dairy component
(100). Furthermore, dietary calcium supplementation in
mice was reported to increase the core temperature, which
was interpreted as an increase in thermogenesis and fat
oxidation (100). However, in a placebo-controlled, cross-
over experiment in overweight human subjects who were
low-calcium consumers, Bortolotti et al. (101) showed that
5 weeks of dairy calcium supplementation at 800 mg d-1 in
these men and women failed to alter adipose tissue lipoly-
sis and lipid oxidation, and furthermore EE under resting
conditions and during acute stimulation with caffeine
(300 mg) was not altered. Similarly, Boon et al. (102)
also reported that calcium supplementation (400–
2,500 mg d-1) to lean young men for a week had no impact
on markers of adipose tissue lipid metabolism nor on
resting EE or fat oxidation. These studies therefore do not
lend support to the hypothesis that dietary calcium per se
plays a role in human energy balance through calcium-
controlled pathways in adipose tissue or through enhanced
thermogenesis. More recently, however, a role for calcium
in combination with vitamin D in the regulation of energy
balance has been proposed by Chan She Ping-Delfos and
Soares (103) on the basis that high calcium and vitamin D
intake at breakfast acutely increased postprandial thermo-
genesis and fat oxidation over two successive meals, and
reduced spontaneous energy intake in the subsequent 24-h
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period. Furthermore, there are reports that obese women
who received mineral tablets containing mainly calcium
and potassium phosphates show signiﬁcant increases in
resting EE than subjects receiving placebo tablets (104).
Interestingly, the addition of K- and Mg-phosphates to
glucose in orange juice drinks has been shown to increase
resting EE by about 15% in obese women (105,106). The
role of minerals and vitamins on EE and substrate oxida-
tion deserves further evaluation.
Protein types and amino acids
It has long been established that, of the three macronutri-
ents, protein has the highest satiating power and greatest
thermic effect compared to isocaloric amounts of carbo-
hydrates or fat – properties that underscore the appeal
for high-protein diets in weight management. There are,
however, concerns that high-protein diets may have long-
term detrimental effects, particularly on renal functions
(107). Consequently, altering the type or source of protein
rather than the amount of protein might represent a safer
and more effective approach for obesity management.
This issue is of particular interest in the light of evidence
indicating that certain protein types or speciﬁc amino
acids supplementation may favour fat oxidation – often
associated with increased BAT growth and/or BAT-UCP1
up-regulation, and hence suggestive of increased SNS
activity – or a shift in nutrient partitioning towards lean
tissue at the expense of fat deposition. Lower adiposity
and improved insulin sensitivity have been reported in
animals fed on diets rich in soy protein (108), ﬁsh protein
(109,110) or whey protein (111,112) when compared to
casein-based diets, as well as in animals fed on diets
supplemented with glycine (113) or glutamine (114).
Supplementation with leucine (115) or arginine (116) has
also been reported to increase nutrient partitioning to lean
body mass at the expense of fat mass accretion, often
accompanied with improved insulin sensitivity. Further-
more, there is also evidence from longitudinal studies in
children (117,118) that higher consumptions of arginine
and lysine are associated with greater gain in lean body
mass and lower gain in fat mass, effects on body compo-
sition that have been attributed to the ability of arginine
and lysine to increase growth hormone secretion and/or
action. To what extent these protein types and speciﬁc
amino acid supplementation also inﬂuence thermogenesis
and fat oxidation is not clear. In humans, only a few
studies have examined the role of protein sources on EE
and substrate oxidation. A study by Mikkelsen et al. (119)
reported a marginally higher 24-h EE (+2%) in subjects
when consuming a pork-meat protein diet than when on a
soy-protein diet for 4 d, but two recent studies comparing
the thermic effects of isocaloric high-protein meals based
upon casein, whey and soy, reported contradictory results.
Whereas whey protein was shown by Acheson et al. (120)
to elicit a greater thermic response (and tendency for
higher fat oxidation) than does protein composed of either
casein or soy, Alfenas Rde et al. (121) found greater fat
oxidation after a breakfast meal containing whey protein
than after meals containing casein or soy protein, but a
higher thermic effect with soy protein than with casein or
whey. Longer-terms studies are warranted in elucidating
whether protein sources and amino acid supplementation
inﬂuence EE and substrate metabolism, while keeping in
mind that excess amino acids and their products can result
in adverse effects (including neurological disorders, oxida-
tive stress and cardiovascular diseases) owing to amino
acid imbalance or antagonism (122).
Carbohydrate types and simple sugars
Differences in postprandial thermogenesis in response to
ingestion of monosaccharides, disaccharides and mixtures
of monosaccharides were ﬁrst documented in humans by
Macdonald and colleagues (123,124), who showed that the
greater thermic effect of sucrose compared to other disac-
charides (maltose and lactose) could be attributed to its
fructose moiety. A greater thermic effect of ingested fruc-
tose than glucose or starch has since been well established
in both lean and obese subjects (125,126), and is to a large
extent explained by the high ATP requirements linked to
fructose-induced gluconeogenesis, with possible contribu-
tion of de novo lipogenesis (125). Although fructose was
initially thought to be advisable for patients with diabetes
because of its low glycaemic index, there is now compelling
evidence in animals, and increasing evidence in humans,
that chronically high consumption of fructose (as sucrose
or as high-fructose corn syrup) can lead to adverse lipid
proﬁle and increased diabetes and cardiovascular risks
(127). This contention is underscored by the recent dem-
onstration that although sustained consumption of glucose-
or fructose-sweetened beverages for 10 weeks led to similar
weight gain in overweight and obese adults, dietary
fructose speciﬁcally increased visceral adiposity and
dyslipidaemia, and decreased insulin sensitivity (128).
Furthermore, chronic energy balance studies comparing
diets enriched with sucrose/fructose or glucose/starch in
laboratory rats and mice have failed to detect differences
between these sugar-enriched diets on whole-body EE and
on the efﬁciency of fat deposition during weight gain (129)
or weight regain (130). These data on energy balance are
consistent with the reported lack of differences in SNS
recruitment of BAT in rats in response to diets in which the
various types of dietary carbohydrates (fructose, sucrose,
dextrose or corn starch) contributed 50% of energy intake
(131). In the coming years, it is likely that more attention
will be directed at the chronic effects of milk sugars (lactose
and its constituent galactose) on energy metabolism. This
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follows the demonstrations in rats that, unlike glucose or
fructose, diets enriched in galactose led to reduced weight
gain associated with markedly increased SNS activity in
epididymal fat pads (132), and that the addition of lactose
to a high-fat diet fed to rats for 12 weeks led to decreased
efﬁciency of fat accumulation (133). Furthermore, the
recent ﬁndings in obese women that oral consumption of
galactose-enriched beverages promotes postprandial fat
mobilization and fat oxidation without adversely affecting
milk production in those who were lactating (134) may
have implications for dietary strategies in the management
of obesity after pregnancy. Finally, in addressing the topic
of carbohydrate types and thermogenesis, it is conceivable
that the physical properties of certain dietary ﬁbres or
non-starch polysaccharides (NSP) can inﬂuence EE by, for
example, increasing the mass and turnover of tissues of
the gastrointestinal tract or via changes in microbiota and
the gut–brain axis controlling thermogenesis. To date,
however, studies conducted over 1–3 weeks in humans
whose diets were either supplemented with NSP (135), or
intrinsically high in NSP relative to a usual mixed diet
(136), have failed to show that increased ingestion of NSP
led to increased 24-h EE beyond the theoretical increase in
heat production due to carbohydrate fermentation.
Whether dietary supplementation with certain speciﬁc
types of ﬁbres may confer thermogenic properties that
could be advantageous for body weight control thus remain
to be demonstrated.
Fat types and fatty acids
Fat in the typical Western diet consists essentially of satu-
rated and unsaturated long-chain triglycerides (LCT),
which are derived from animal fat and vegetable oils.
In some countries, medium-chain triglycerides (MCT),
derived from coconut oil and palm oil, are also an impor-
tant component of fat intake. While LCT yields fatty acids
which have chain length exceeding 12 carbons (usually
C14-C22), MCT yields fatty acids which have carbon
length lower than 12 (usually C6-C10). The diversity in
fatty acid structure resulting from differences in chain
length, degree of unsaturation, and position and stereoiso-
meric conﬁguration of the double bonds may affect the
metabolic fate of the fatty acid and the rate of fatty acid
oxidation. The general trend in animal and human studies
measuring fatty acid oxidation using isotope-labelled fatty
acids (137) or indirect calorimetry can be summarized as
follows:
1. Oxidation of saturated fatty acids decreases with
increasing carbon (C) length (laurate C12 > myristate
C14 > palmitate C16 > stearate C18), with medium-chain
fatty acids (8–12 carbons) being oxidized the most rapidly.
2. Oxidation rates of long-chain unsaturated fatty acids
(oleic, linoleic, linolenic) are more rapid than those for
long-chain saturated fatty acids (palmitic, stearic).
3. Differences in oxidation rates between various sub-
types unsaturated fatty acids (oleic vs. linoleic vs. linolenic)
are less clear, whether between monounsaturated fatty
acids (MUFAs) and polyunsaturated fatty acids (PUFAs) or
between n3-PUFA and n6-PUFA.
There are indeed several acute studies in humans
showing that the thermic effects of meals rich in MCT are
greater than those rich in LCT or that diets high in PUFAs
or MUFAs are more thermogenic than those high in satu-
rated fatty acids (6,138–141), with no differences between
meals rich in PUFAs versus MUFAs in postprandial ther-
mogenesis (141,142). A dose–response study in a respira-
tory chamber investigating the thermogenic potential of
MCT, when consumed as an integral part of the typical
Western diet in non-obese men, has shown that 5–10 g of
MCT ingested with each of the three meals (breakfast,
lunch and dinner), in substitution of LCT, was well toler-
ated and caused a 5% increase in 24-h EE (143), which
resulted from increases in both fat and carbohydrate oxi-
dation. Several mechanisms have been put forward to
explain the thermogenic effects of MCT, and these centre
upon its unique absorption and metabolic fate (through
metabolic pathways which are energetically more costly),
rapid entry in the mitochondrial oxidation pathway
without requirement for carnitine and activation of the
SNS (138). The ﬁndings that the elevation in 24-h EE with
increasing dietary ratio of MCT : LCT (143) was associ-
ated with augmented urinary excretion rate of NA also
suggest a speciﬁc role for enhanced SNS activity contribut-
ing to the thermogenic effects of MCT. The possibility that,
on a cumulative basis, the increased EE with consumption
of diets rich in MCT can have a signiﬁcant impact on body
weight and body composition is supported by the demon-
strations that consumption of a diet rich in MCT for 4
weeks results in greater loss of adipose mass than with LCT
(144). Furthermore, consumption of MCT oil (18–24 g)
daily for 16 weeks as part of a weight-loss plan improves
the losses in body weight and body fat (by about 1.5 kg)
without adverse metabolic proﬁle compared with olive oil
(145), thereby underscoring the suggestion that MCT can
be considered as safe functional food ingredient. More
recently, dietary supplementation with PUFA-(linoleic)-rich
safﬂower oil (8 g d-1) for 36 weeks has also been reported
to reduce trunk fat, increase lean mass and improve glucose
proﬁle in obese women with type 2 diabetes (146).
Although supplementation with conjugated linolenic acid
resulted in reduced adipose mass, there was no improve-
ment in lean body mass nor in glucose proﬁle (146). That
diminished body fat with PUFA-enriched diets may result in
part from enhanced thermogenesis and in part from nutri-
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ent partitioning in favour of lean body mass was recently
documented in rats showing weight regain after caloric
restriction (147). The results of these studies involving iso-
caloric refeeding on high-fat diets varying in fatty acid
composition demonstrate that (i) independently of the
n6 : n3 ratio, linoleic acid and a-linolenic acid reduce the
efﬁciency of fat deposition, and that (ii) their main metabo-
lites – arachidonic acid and docosahexaenoic acid (DHA),
respectively – induce disproportionately greater reduction
in the efﬁciency of fat regain. Taken together, the possibility
therefore arises that diets enriched with PUFA as
linoleic acid and/or a-linolenic acid, or with their main
metabolites, in particular DHA (147) or DHA derivatives
(148), may have relevance as functional food ingredients
for enhancing thermogenesis, improving body composition
and insulin sensitivity in humans.
Multiple targets and common targets
From the overview above, one could conclude that in the
present state-of-knowledge, the compounds categorized
undermethylxanthines, polyphenols, capsinoids and certain
fatty acids (MCT and PUFA) confer the greatest potential as
stimulators of thermogenesis and fat oxidation in obesity
management. It is therefore not surprising that there is
currently considerable impetus towards developing nutra-
ceutical and functional food products that contain various
combinations of these ingredients, particularly in the light of
evidence that in addition to inﬂuencing resting EE and 24-h
EE, theymay also contribute to negative fat balance through
their effects in increasing spontaneous physical activity (e.g.
caffeine), in reducing fat absorption (e.g. calcium, catechin
polyphenols) or in promoting satiety (caffeine, capsaicins
and MCT). Indeed, the view that targeting thermogenesis
will almost inevitably lead to compensatory increase in food
intake is not supported by the demonstrations over the past
decades that, like the numerous b3-adrenoceptor agonists
that have been screened (34,149), the administration of the
bioactive food ingredients with thermogenic potentials dis-
cussed above either reduced energy intake or had no impact
on food intake (6,73,76,99,144).
Molecular–physiological targets
Keeping in mind that the mechanistic basis underlying the
impact of such widely varying classes of compounds on
thermogenesis and fat metabolism is likely to involve a
multitude of targets in tissues/organs, it is nonetheless of
interest to underscore the fact that, based on human and
animal studies, they all seem to share two main ‘global’
peripheral targets. They not only exert their effects on the
sympathoadrenal system and catecholamine actions (i.e. as
sympathomimetics) thereby leading to enhance thermogen-
esis, but also are capable of stimulating fatty acid oxidation
per se via the AMPK signalling pathway leading to ACC
inhibition (i.e. ACC inhibitors). Indeed, there is evidence,
from both in vitro and in vivo studies in rodents, that the
AMPK–ACC pathway leading to enhanced ﬂux of fatty
acids in the mitochondrial b-oxidation can be modulated
by caffeine or capsaicin-like compounds in skeletal muscle
(150–152), by salicylates in the liver (153), by catechin
polyphenols in liver, adipose tissue and skeletal muscle
(154), by numerous other polyphenols that include resvera-
trol, catechins, curcumin, genistein, quercetin, kaempferol
and isoﬂavones in several tissues (155–157) or by PUFA in
liver and skeletal muscle (158). Furthermore, the fact that
increasing the fatty acid availability increases AMPK activ-
ity independent of changes in the cellular energy charge
supports the view that fatty acids may modulate AMPK
allosterically (158). A mechanistic model integrating the
mechanisms by which these bioactive ingredients – as sym-
pathomimetics and ACC inhibitors – may be operating in
coordination to enhance thermogenesis and fat oxidation is
presented schematically in Fig. 4.
Skeletal muscle and brown adipose tissue targets
Which organs and tissues contribute most importantly to
the thermogenic effects of these bioactive food ingredients
is uncertain, amidst decades-old controversies about the
importance of skeletal muscle as a major site of
sympathomimetic-mediated thermogenesis (159–161) and
about the amount and functionality of BAT in adult
humans (162). The notion of targeting BAT for enhancing
thermogenesis in human obesity management has recently
been revitalized by investigations, using positron emission
tomography coupled to computed tomography (PET/CT)
scanning, which have revealed the presence of substantial
amount of BAT in neck and shoulder region that become
apparent by relatively short exposure to mild cold through
increased SNS activity (162,163). A more recent study
(164) has revealed the presence of UCP1 in supraclavicular
adipose tissue even when the results of PET/CT scans are
negative (most likely due to suboptimal sensitivity of stan-
dard PET/CT), thereby reinforcing the contention that the
prevalence of BAT is higher than so far recognized in adult
humans. As the thermogenic effects of xanthines, polyphe-
nols, capsaicin-like compounds and PUFA have all been
shown to be capable of stimulating the SNS–BAT axis in
rodents (18,63,76,93,165), the plausibility that these bio-
active food ingredients, via their sympathomimetic proper-
ties, could be exerting part of their thermogenic effects
through (re)activation of BAT in humans can no longer be
disregarded. Indeed, based on data about the high rate
of O2 consumption of this tissue in response to NA in
hyperphagic rats exhibiting diet-induced thermogenesis
(1.7 mL O2 g-1 min-1), Rothwell and Stock (166) have
argued that the activation of some 50 g of active BAT by
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NA in an average ‘sedentary’ man spending 2,500 kcal d-1
would indeed correspond to an increase of about 20% in
daily EE. Thus, although the role of BAT in the regulation
of energy balance in humans has yet to be established, an
apparently trivial amount of this tissue, if activated, could
have a profound inﬂuence on energy balance, as 10–20%
of daily EE (i.e. 250–500 kcal) can make the difference
between maintaining body weight or gaining 10–20 kg in a
year. Indeed, an increase in daily EE of 10–20% corre-
sponds to the level of diet-induced thermogenesis demon-
strated among the more obesity-resistant participants in
long-term human overfeeding studies that involved mea-
surements of total EE (167,168). Whether these values
represent the maximal increase in (non-shivering) ther-
mogenic capacity in humans is at present unknown, but in
animals the maximal thermogenic capacity can be mark-
edly increased through stimulation of BAT growth induced
by sympathetic and thyroid hormone activation of adipo-
cyte differentiation/proliferation (162,166). The search for
pharmaceutical and nutraceutical products that may
increase the amount and activity of this BAT is therefore an
appealing strategy for the management of human obesity
via stimulation of metabolic rate in a tissue whose primary
function is to produce heat.
Figure 4 Main pathways in neuro-hormonal control of thermogenesis and fat oxidation, and possible molecular targets for bioactive food ingredients,
namely along the NA–cAMP pathway and along the AMPK–ACC2 pathway. From a physiological standpoint, leptin and insulin can act both centrally
via SNS–NA–cAMP axis and peripherally via leptin receptors (Ob-Rb) and insulin receptors (IR), respectively, to inﬂuence thermogenesis fuelled by
fat oxidation (Fat OX) and carbohydrate oxidation (CHO OX). Moreover, adrenoceptor stimulation of the deiodinase II enzyme (DII) can enhance
peripheral conversion of the thyroid hormone T4 to its biologically more active form T3, which in turn can, like leptin, modulate the AMPK–ACC
pathway that exerts control over fatty acid oxidation. Note that all the bioactive food ingredients depicted here have the dual property of modulating
both the NA–cAMP pathway and AMPK–ACC pathway, i.e. they function as both sympathomimetics and ACC2 inhibitors in enhancing thermogenesis
fuelled by fat oxidation. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; NA, noradrenaline; SNS, sympathetic nervous system.
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Cardiac responses to stimulation of thermogenesis
A concern that is often raised about strategies to manage
obesity by targeting thermogenesis is that it will result in an
increased heart rate. Indeed, as EE increases, the work done
by the heart must also increase to meet the body’s greater
demand for oxygen. During exercise, there is a fairly close
relationship between heart rate and EE to the extent that
the ﬁeld technique for continuously measuring heart rate
has been used to estimate EE in humans. However, the
relationship between EE and heart rate is curvilinear, and at
low levels of EE, heart rate does not increase as steeply for
a given change in EE, probably because of changes in stroke
volume. Consequently, an increase in heart rate in response
to an extra demand in oxygen resulting from a 10–20%
increase in daily EE is likely to be marginal. It is, however,
probable that a substantial increase in heart rate driven by
much greater increases in daily EE will not be considered as
clinically acceptable.
Concluding remarks
The use of dietary supplements, botanical/herbal prepara-
tions, nutraceuticals and functional foods in the manage-
ment of body weight has generally been perceived by the
medical establishment as essentially anecdotal. This is
largely because there is little, if any, robust scientiﬁc data
to support claims of anti-obesity efﬁcacy for the vast
majority of such products that are being proposed to the
consumers. Unlike prescription and over-the-counter
medications, the ‘natural’ dietary adjuvants currently on
the market are not prospectively reviewed for safety and
efﬁcacy by major regulatory agencies, which only inter-
vene if a given dietary supplement product is shown to
present ‘a signiﬁcant or unreasonable risk’. Consequently,
most of these products have not been studied in long-term
prospective placebo-controlled clinical trials and reported
in peer-reviewed medical journals. Nonetheless, it is a
reality that many of these products do in fact contain one
or more pharmacologically active ingredient that is
known to possess thermogenic and fat-oxidizing proper-
ties in acute studies, but the question is always whether
they are effective and safe at the doses prescribed and
over the long term. With research likely to generate many
new candidate bioactive food ingredients, with the market
likely to be overwhelmed with new products containing
combinations of these ingredients and with claims of a
more effective multi-targeted approach for weight control,
the challenge for regulatory agencies is to decide as to
what type of safety and efﬁcacy standards these single-
target or multi-target products should be subjected before
being ‘approved’ as supplements or functional foods for
the purpose of managing human obesity. In the meantime,
it is relevant to draw attention to the fact that among the
caffeine-containing beverages, catechins-containing green
tea, spices rich in capsaicinoids/capsinoids, and oils rich
in MCT, PUFA or DHA, there is likely to be at least one
(and generally two or more) of these dietary ingredients
that form an integral part of the diet in most cultures of
the world today. It makes one wonder about the extent to
which they could already be helping many of us to put
our excess fat into the ﬁre.
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